In the ischemic phase of MI or at the beginning of reperfusion, intravenous administration of an inhibitor of p38 MAPK, SB203580, can reduce the occurrence of ventricular tachycardia/ventricular fibrillation, which is related to increasing the phosphorylation level of Cx43 [37]. This evidence concerns the gene GJA1 and myocardial infarction.